Clinical Trials

If you or a loved one suffers from mild cognitive impairment or have been diagnosed with early Alzheimer’s Disease, you’ve likely followed the news over the last few months about a new treatment awaiting FDA approval. Well, that FDA approval has arrived: Leqembi, a medication that targets the amyloid plaques…

If there are days you wish you could tell your body’s aging process just to slow down, or times you wish you could capture some of the energy and vitality you felt as a younger person, you’re not alone. Most of us would relish feeling more youthful and extending our…

For the more than 6 million Americans currently thought to have Alzheimer’s, and their loved ones, the possible benefits of new medications can’t come soon enough. As the most common cause of dementia, Alzheimer’s Disease predominantly afflicts older women (⅔ of Alzheimer’s patients are female) and almost ¾ of those…

As a follow-up to our previous article portending the next new drug for Alzheimer’s, the FDA has now given approval under its accelerated approval pathway to the new medication Leqembi (originally known as Lecanemab). This drug was developed to help slow down cognitive decline in those with Mild Cognitive Impairment…

You may remember that more than a year ago, we posted a story on the arrival of a new drug approved by the FDA for the treatment of Alzheimer’s disease. That drug is Aduhelm, and while it is technically on the market and available, its use has been greatly limited…

It’s been almost 2 decades since the FDA approved any new therapeutics for the treatment of Alzheimer’s Disease. In that time, patients and families – as well as their care providers- have struggled with the reality of limited benefit from current medication options and a failure rate of 98.5% of…